hold on there's just too much going on in Congress lmao...
Medicaid must cover whole genome or exome sequencing for kids with suspected genetic disorders.
Rep. Scott Peters (D-CA) with bipartisan cosponsors.
Introduced in House, referred to Energy and Commerce Committee.
The bill requires state Medicaid programs to cover whole genome and whole exome sequencing for children under 21 when ordered by a doctor as a first test for a suspected genetic disorder, rare disease, or condition of unknown origin—including developmental delays or intellectual disabilities. The testing must be paid separately, not bundled with other services. Sponsor Rep. Peters (D-CA) leads a bipartisan group including Rep. Bilirakis (R-FL) and Rep. Veasey (D-TX). The bill is in the House Energy and Commerce Committee; no vote has been scheduled.
Introduced Jan 15, 2026
This bill is under review by a committee. The committee holds hearings, gathers testimony from experts and stakeholders, and may propose amendments. If the committee votes to advance it, the bill moves to the full chamber for debate and a vote.
Children on Medicaid with conditions like global developmental delay, intellectual disability, or multiple birth defects could get a single genetic test to identify the cause. The bill explicitly allows whole genome sequencing (reads all DNA) and whole exome sequencing (reads protein-coding genes). The separate payment rule means hospitals and labs would be paid directly for the test, avoiding potential billing confusion. However, the bill does not set test pricing; it directs federal agencies to study costs and barriers after two years.
Supporters Say
Supporters argue that early genetic diagnosis can end diagnostic odysseys, improve care, and save Medicaid money by avoiding unnecessary tests and treatments.
Critics Say
Critics worry about high costs of sequencing, potential for misuse of genetic data, and state budget pressures from an unfunded mandate.
Supporters point to studies where genome sequencing found causes in 30-50% of previously undiagnosed children, enabling targeted therapies. Critics, including some fiscal conservatives, note that a single genome test can cost thousands of dollars and that states must cover it without extra federal funds. Privacy advocates may also raise concerns about storing children's genetic data, though the bill does not address data protections beyond standard Medicaid rules.